LENVIMA(R) (lenvatinib) in Combination with Pembrolizumab and Transarterial Chemoembolization (TACE) Approved in China for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma Eisai Jul 29, 2025 08:01 HKT/SGT Read More
China Medical System (867.HK, 8A8.SG) NDA for the Improved New Drug ZUNVEYL for Alzheimer's Disease Accepted in China China Medical System Holdings Limited Jul 29, 2025 05:00 JST Read More
Olympus Enters Strategic Partnership to Develop Endoluminal Gastrointestinal Robotics Olympus Jul 25, 2025 16:00 JST Read More
Olympus Enters Strategic Partnership to Develop Endoluminal Gastrointestinal Robotics Olympus Jul 25, 2025 15:00 HKT/SGT Read More
Multi-Dose Diquafosol Sodium Eye Drops Obtained Approval from NMPA for Commercialisation in China Essex Bio-Technology Limited Jul 25, 2025 11:52 JST Read More
Everest Medicines Announces Share Placement to Raise Approximately HK$1,572.50 Million Everest Medicines Limited Jul 25, 2025 11:01 JST Read More
HKTDC Research Report: Exploring Opportunities in Hong Kong's Proprietary Chinese Medicine Industry HKTDC Jul 24, 2025 18:43 JST Read More
Launch of Beova(R) Tablets in Thailand for Overactive Bladder Eisai Jul 23, 2025 09:07 HKT/SGT Read More
Crown Bioscience San Diego Achieves CLIA Certification to Enhance Clinical Trial Support Crown Bioscience Jul 23, 2025 09:00 HKT/SGT Read More
Eisai To Present Four-Year Efficacy And Safety Data On Continuous Treatment With Lecanemab At The Alzheimer's Association International Conference 2025 Eisai Jul 22, 2025 10:56 HKT/SGT Read More
A New Chapter Begins! CMS Achieves Secondary Listing on the Singapore Exchange Main Board Today China Medical System Holdings Ltd. Jul 16, 2025 16:00 JST Read More
Eisai Awarded "The 9th Bioindustry Award" for Drug Discovery Research for Anti- Amyloid B Monoclonal Antibody Lecanemab Eisai Jul 16, 2025 13:50 HKT/SGT Read More
Fujitsu and Acer Medical trial AI service that assesses future disease risk in elderly patients through gait pattern abnormality detection Fujitsu Ltd Jul 16, 2025 09:20 HKT/SGT Read More
"URECE" (Dotinurad) Launched in China as a treatment for Gout Eisai Jul 14, 2025 09:20 HKT/SGT Read More
エーザイ、CDP から「サプライヤー・エンゲージメント評価」において最高評価である「サプライヤー・エンゲージメント・リーダー」に選定 Eisai Jul 08, 2025 09:00 JST Read More
Eisai Selected as Supplier Engagement Leader, CDP's Highest Rating in the Supplier Engagement Assessment Eisai Jul 08, 2025 08:31 HKT/SGT Read More
